<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721537</url>
  </required_header>
  <id_info>
    <org_study_id>15-006870</org_study_id>
    <nct_id>NCT02721537</nct_id>
  </id_info>
  <brief_title>Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes</brief_title>
  <acronym>TRMC-004</acronym>
  <official_title>Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes and a Comparison of the Effect of Nicotinamide Riboside Supplementation on Brain NAD+ Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thorne Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can nicotinamide riboside (750 mg/day for 12 weeks) affect the levels of NAD+ in the brain as
      measured by 31P MRS?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy collegiate athletes (football, soccer, rugby, hockey, and volleyball) will take
      Nicotinamide Riboside (NR) or placebo twice daily for 84 days. Pre- and post-intervention
      evaluations include physical assessment, blood tests for safety and toxicity monitoring,
      blood tests for biomarkers, neurologic testing, quality of life questionnaires, and the 31P
      MRI exam.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in brain NAD+ levels</measure>
    <time_frame>baseline, day 84</time_frame>
    <description>As measured by 31P MRI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Concussion, Mild</condition>
  <arm_group>
    <arm_group_label>Arm A: Healthy Collegiate Athletes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy collegiate athletes will take active Nicotinamide Riboside</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Healthy Collegiate Athletes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy collegiate athletes will take a matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide Riboside</intervention_name>
    <description>Three capsules, twice per day for 84 days</description>
    <arm_group_label>Arm A: Healthy Collegiate Athletes</arm_group_label>
    <other_name>Niagen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Three matching capsules, twice per day for 84 days</description>
    <arm_group_label>Arm B: Healthy Collegiate Athletes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult current and former (within 2 years) collegiate athletes (football, rugby,
             soccer, hockey, and volleyball)

          -  Body mass index (estimated based on height and weight) from 23 to 37

          -  Willing to provide informed consent, ingest test substance, and provide blood
             specimens

          -  Willing to comply with study instructions and maintain current level of physical
             activity throughout the study

        Exclusion Criteria:

          -  History of loss of consciousness of more than 5 minutes

          -  Contraindications to Magnetic Resonance Imaging (MRI), such as implanted medical
             devices, metal objects, or pacemakers

          -  History of epilepsy

          -  History of more than 3 concussions

          -  History of headache preceding a concussion

          -  History of depression preceding a concussion

          -  History of developmental delays or Attention Deficit Hyperactivity Disorder (ADHD)

          -  History of post-traumatic seizures

          -  History of complex spine and/or skull trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent A. Bauer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester, MN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Lindeen, RN</last_name>
    <phone>507-284-4799</phone>
    <email>athletesstudy@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shawn C Fokken, CCRP</last_name>
    <phone>507-284-4799</phone>
    <email>athletesstudy@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota Center for Magnetic Resonance Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Valenzuela, RAC</last_name>
      <phone>612-624-9926</phone>
      <email>majes014@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Xiao-Hong Zhu, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn Fokken</last_name>
      <phone>507-293-2740</phone>
      <email>athletesstudy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Brent A Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Brent A. Bauer</investigator_full_name>
    <investigator_title>M.D., Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Brain Nicotinamide Adenine Dinucleotide (NAD+)</keyword>
  <keyword>Adenosine Triphosphate (ATP) Depletion</keyword>
  <keyword>Polyadenosine Diphosphate-Ribosepolymerase (PARP) Activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Concussion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

